Status of particle therapy for lung cancer

Acta Oncologica

Volumn 50, Issue 6, 2011, Pages 745-756

  Liao, Zhongxing ^a   Lin, Steven H ^a   Cox, James D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DERMATITIS; DOSIMETRY; ESOPHAGITIS; FATIGUE; HUMAN; ION THERAPY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; PARTICLE RADIATION; PHOTON THERAPY; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION PNEUMONIA; RELATIVE BIOLOGIC EFFECTIVENESS; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; THORAX PAIN;

HUMANS; LUNG NEOPLASMS; PHOTONS; PROTONS;

EID: 79960534158     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.590148     Document Type: Review

References (49)

1. International Agency for Research on Cancer W. lung cancer incidence and mortality worldwide in 2008. Globocan 2008 Cancer Fact Sheet, 2008.
2. Lee CHM, Tait D, Nahum AE, Webb S. Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC). Br J Radiol 1999;72:1078-84.
3. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Signifi cant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:1087-96.
4. Macdonald OK, Kruse JJ, Miller JM, Garces YI, Brown PD, Miller RC, et al. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carci-noma: A comparative dosimetric analysis. Int J Radiat Oncol Biol Phys 2009;75:950-8.
5. Register SP, Zhang X, Mohan R, Chang JY. Proton stereotac-tic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010 Epub Jul 7.
6. Hoppe BS, Huh S, Flampouri S, Nichols RC, Oliver KR, Morris CG, et al. Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: A dosimetric com-parison with photon-based stereotactic body radiotherapy. Radiother Oncol 2010;97:425-30.
7. Wang C, Nakayama H, Sugahara S, Sakae T, Tokuuye K. Comparisons of dose-volume histograms for proton-beam ver-sus 3-D conformal X-ray therapy in patients with stage I non-small cell lung cancer. Strahlenther Onkol 2009;185:231-4.
8. Auberger T, Seydl K, Futschek T, Sztankay A, Sweeney RA, Lukas P. Photons or protons: Precision radiotherapy of lung cancer. Strahlenther Onkol 2007;183:3-6.
9. Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radia-tion therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: A virtual clinical study. Int J Radiat Oncol Biol Phys 2010;77:357-66.
10. Moyers MF, Miller DW, Bush DA, Slater JD. Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys 2001;49:1429-38. (Pubitemid 32294322)
11. Engelsman M, Kooy HM. Target volume dose considerations in proton beam treatment planning for lung tumors. Med Phys 2005;32:3549-57.
12. Kang Y, Zhang X, Chang JY, Wang H, Wei X, Liao Z, et al. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys 2007;67:906-14. (Pubitemid 46215899)
13. Hui Z, Zhang X, Starkschall G, Li Y, Mohan R, Komaki R, et al. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys 2008;72:1385-95.
14. Bjelkengren G, Glimelius B. The potential of proton beam radiation therapy in lung cancer (including mesothelioma). Acta Oncol 2005;44:881-3. (Pubitemid 41780114)
15. Pijls-Johannesma M, Grutters JPC, Lambin P, Ruysscher DD. Particle therapy in lung cancer: Where do we stand? Cancer Treat Rev 2008;34:259-67.
16. Pijls-Johannesma M, Grutters JPC, Verhaegen F, Lambin P, De Ruysscher D. Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A sys-tematic literature review. Oncologist 2010;15:93-103.
17. Grutters JPC, Kessels AGH, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis. Radiother Oncol 2010;95:32-40.
18. Grutters JP, Pijls-Johannesma M, Ruysscher DD, Peeters A, Reimoser S, Severens JL, et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research. Cancer Treat Rev 2010;36:468-76.
19. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (Hypo-FXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-100.
20. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-31. (Pubitemid 41628038)
21. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;72:967-71.
22. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6.
23. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623-31. (Pubitemid 39318910)
24. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-9. (Pubitemid 46630909)
25. Bush DA, Slater JD, Bonnet R, Cheek GA, Dunbar RD, Moyers M, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest 1999;116:1313-9. (Pubitemid 29535986)
26. Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest 2004;126:1198-203. (Pubitemid 39391251)
27. Bush DA, Do SY, Slater JD. Comorbidity-adjusted survival in early stage lung cancer patients treated with hypofraction-ated proton therapy. J Oncol 2010;2010:251208. Epub 2010 Dec 1.
28. Shioyama Y, Tokuuye K, Okumura T, Kagei K, Sugahara S, Ohara K, et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56:7-13. (Pubitemid 36403671)
29. Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose pro-ton beam therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:107-11.
30. Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys Epub 2011 Jan 18.
31. Iwata H, Murakami M, Demizu Y, Miyawaki D, Terashima K, Niwa Y, et al. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer 2010; 116:2476-85.
32. Peeters A, Grutters JPC, Pijls-Johannesma M, Reimoser S, De Ruysscher D, Severens JL, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol 2010; 95:45-53.
33. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medi-cally inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:3290-6. Epub 2009 May 4.
34. Miyamoto T, Baba M, Yamamoto N, Koto M, Sugawara T, Yashiro T, et al. for the Working Group for Lung Cancer. Curative treatment of stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007;67:750-8. (Pubitemid 46215886)
35. Miyamoto T, Baba M, Sugane T, Nakajima M, Yashiro T, Kagei K, et al. for Working Group for Lung Cancer. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2007;2:916-26. (Pubitemid 47511595)
36. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemo-therapy plus high-dose radiation versus radiation alone in Stage III non-small-cell lung cancer. N Engl J Med 1990; 323:940-5. (Pubitemid 20332333)
37. Arriagada R, Le Chevalier T, Quoix E, Ruffi e P, de Cremoux H, Douillard JY, et al. ASTRO (American Society for Thera-peutic Radiology and Oncology) plenary: Effect of chemo-therapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (F é deration Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists.. Int J Radiat Oncol Biol Phys 1991; 20:1183-90.
38. Schaake-Koning C, Maat B, Van Houtte P, van den Bogaert W, Dalesio O, Kirkpatrick A, et al. Radiotherapy combined with low-dose cis-diammine dichloroplatinum (II) (CDDP) in inoperable nonmetastatic non-small cell lung cancer (NSCLC): A randomized three arm phase II study of the EORTC Lung Cancer and Radiotherapy Cooperative Groups. Int J Radiat Oncol Biol Phys 1990;19:967-72. (Pubitemid 20345167)
39. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17: 2692-9. (Pubitemid 29415225)
40. Curran WJ, Scott CB, Langer CJ, Komaki R, Lee J, Hauser S, et al. Long-term Benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 (abstract 2499). Proc Am Soc Clin Oncol 2003;22:621.
41. Wei X, Liu HH, Tucker SL, Liao Z, Hu C, Mohan R, et al. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:100-7. (Pubitemid 44175670)
42. Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58: 1258-67. (Pubitemid 38314812)
43. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys2007;68: 94-102. (Pubitemid 46589835)
44. Liao ZX, Komaki RR, Thames Jr HD, Liu HH, Tucker SL, Mohan R, et al. Infl uence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemora-diotherapy. Int J Radiat Oncol Biol Phys 2010;76:775-81
45. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, et al. Early fi ndings on toxicity of proton beam therapy with con-current chemotherapy for nonsmall cell lung cancer. Cancer Epub 2011 Jan 24. doi: 10.1002/cncr.25848.
46. Komaki R, Sejpal SV, Wei X, Allen P, Chang JY, Liao Z, et al. Reduction of bone marrow suppression for patients with stage III NSCLC treated by proton and chemotherapy compared with IMRT and chemotherapy (abstract). Presented at Particle Therapy Cooperative Group (PTCOG) 47, May 19-24, 2008, Jacksonville, FL.
47. Nakayama H, Satoh H, Sugahara S, Kurishima K, Tsuboi K, Sakurai H, et al. Proton beam therapy for stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys Epub 2010 Sep 30.
48. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, et al. Phase 2 study of high-dose proton therapy with con-current chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer Epub 2011 Mar 22. doi: 10.1002/ cncr.26080.
49. Mohan R, Zhang X, Matney J, Bluett J, Dong L, Balter P, et al. IMRT vs. passively scattered proton therapy (PSPT) for locally advanced non-small cell lung cancer (LA NSCLC) randomized trial-is there equipoise? (abstract 1137). Int J Radiat Oncol Biol Phys 2010;78:S201-2.